Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-13 · accession 0001201096-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-17 | 2026-02-13 | NBIX | GORMAN KEVIN CHARLES | Dir | F - Tax | $124.12 | -40.3K | 519.5K | -7% | -$5.00M |
| D | 2026-02-17 | 2026-02-13 | NBIX | GORMAN KEVIN CHARLES | Dir | A - Grant | $0.00 | +63.7K | 585.7K | +12% | $0 |
| DM | 2026-02-17 | 2026-02-13 | NBIX | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | +11.0K | 524.9K | +2% | $0 |
| DM | 2026-02-17 | 2026-02-13 | NBIX | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | -11.0K | 11.2K | -49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-13 | F | D | 34,380 | $124.12 | 551,293 | D | — | — | (F1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. (F3) 551,293 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. |
| 2 | Common | Common Stock | 2026-02-13 | A | A | 63,724 | $0.00 | 585,673 | D | — | — | (F2) On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. |
| 3 | Common | Common Stock | 2026-02-13 | F | D | 2,901 | $124.12 | 521,949 | D | — | — | (F1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. |
| 4 | Common | Common Stock | 2026-02-13 | M | A | 5,604 | $0.00 | 522,497 | D | — | — | |
| 5 | Common | Common Stock | 2026-02-13 | F | D | 3,024 | $124.12 | 519,473 | D | — | — | (F1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. |
| 6 | Common | Common Stock | 2026-02-13 | M | A | 5,377 | $0.00 | 524,850 | D | — | — | |
| 7 | Derivative | Restricted Stock Unit | 2026-02-13 | M | D | 5,377 | $0.00 | 5,377 | D | — · — to — | 5,377 Common Stock | (F4) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F6) This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, vested as to 5,377 shares on February 13, 2026, and will vest as to 5,377 shares on February 13, 2027, subject to the terms and conditions of the award. |
| 8 | Derivative | Restricted Stock Unit | 2026-02-13 | M | D | 5,604 | $0.00 | 11,208 | D | — · — to — | 5,604 Common Stock | (F4) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F5) This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, vested as to 5,604 shares on February 13, 2026, and will vest as to 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award. |